Anatomic Snuffbox (Distal Radial Artery) and Radial Artery Access for Treatment of Intracranial Aneurysms with FDA-Approved Flow Diverters
Anna Luisa Kühn, Sudhakar R Satti, Tim Eden, K de Macedo Rodrigues, Jasmeet Singh, Francesco Massari, Matthew J. Gounis, Ajit S Puri
Abstract
<h3>BACKGROUND AND PURPOSE:</h3> Transradial access for neurointerventional procedures has been proved a safer and more comfortable alternative to femoral artery access. We present our experience with transradial (distal radial/anatomic snuffbox and radial artery) access for treatment of intracranial aneurysms using all 3 FDA-approved flow diverters. <h3>MATERIALS AND METHODS:</h3> This was a high-volume, dual-center, retrospective analysis of each institution’s data base between June 2018 and June 2020 and a collection of all patients treated with flow diversion via transradial access. Patient demographic information and procedural and radiographic data were obtained. <h3>RESULTS:</h3> Seventy-four patients were identified (64 female patients) with a mean age of 57.5 years with a total of 86 aneurysms. Most aneurysms were located in the anterior circulation (93%) and within the intracranial ICA (67.4%). The mean aneurysm size was 5.5 mm. Flow diverters placed included the Pipeline Embolization Device (Flex) (PED, <i>n</i> = 65), the Surpass Streamline Flow Diverter (<i>n</i> = 8), and the Flow-Redirection Endoluminal Device (FRED, <i>n</i> = 1). Transradial access was successful in all cases, but femoral crossover was required in 3 cases (4.1%) due to tortuous anatomy and inadequate support of the catheters in 2 cases and an inability to navigate to the target vessel in a patient with an aberrant right subclavian artery. All 71 other interventions were successfully performed via the transradial approach (95.9%). No access site complications were encountered. Asymptomatic radial artery occlusion was encountered in 1 case (3.7%). <h3>CONCLUSIONS:</h3> Flow diverters can be successfully placed via the transradial approach with high technical success, low access site complications, and a low femoral crossover rate.